Emcure Pharma launches weight loss drug Poviztra in India
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Subscribe To Our Newsletter & Stay Updated